// App-Quantinova.ai

TCT-397 : Edoxaban versus Standard of Care and their Effects on Clinical Outcomes in Patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation – Rationale and Design of the ENVISAGE-TAVI AF Trial

Researchers

Presenter

  • Nicolas Van Mieghem

Principal Investigators

  • Marco Valgimigli

  • Roxana Mehran

  • Eric Boersma

  • Usman Baber

  • Christian Hengstenberg

  • Minggao Shi

  • Roland Vranckx

Medical Centers

  • Deutsches Herzzentrum Munchen, Munich, Germany

  • Thorax Center, Erasmus Medical Center, Rotterdam, Netherlands

  • Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, New York, New York, United States

  • Hartcentre Hasselt, Hasselt, Belgium

  • Daiichi Sankyo Pharma Development, Basking Ridge, New Jersey, United States

  • Swiss Cardiovascular Center, Inselpsital, Bern, Switzerland

Locations

  • Germany

  • United States

  • Netherlands

  • Belgium

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Genetic Disorder

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Central Nervous System (CNS)

Disease

  • Myocardial infarction

  • Arrhythmia

  • Ischemic stroke

  • Venous thrombosis

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Edoxaban

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • NCT02943785

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved